Table 2.

Antitumor activity of P276-00 and cisplatin in clonogenic assay

Tumor type
P276-00 (μmol/L)
Cisplatin (μmol/L)
Total of 22 xenograftsIC50IC70IC50IC70
CNS
    CNXF SF268/6N0.200.4186.39179.46
Colorectal
    CXF 1103/22N4.8676.2643.1489.61
    CXF 243/8N1.777.495.6242.98
    CXF 280/19M1.042.6317.0134.55
Gastric
    GXF 251/15N1.573.8738.9182.80
Lung
    LXFE 397/18N0.250.552951.58
    LXFA 297/19N0.5912.11>100>100
    LXFL 529/12N0.572.3822.8746.97
Breast
    MAXF 857/35N1.042.639.65>100
    MAXF MX1/17M1.633.394.799.08
    MAXF 401/31N0.070.260.5621.16
Melanoma
    MEXF 514/20N0.541.150.622.54
    MEXF 462/16N0.310.5511.1031.62
    MEXF 276/25N0.270.46>100>100
Ovary
    OVXF 1023/28N0.641.6118.1138.07
Prostate
    PRXF 22RVI/7N0.210.5034.90130.10
    PRXF DU145/14N2.024.25>100>100
    PRXF PC3MX/16N2.744.6063.80196.19
Renal
    RXF 393/11N0.200.410.8124.33
    RXF 944LX/4N20.400.708.0722.67
Sarcoma
    SXF 1301/6N0.410.817.2624.24
Mean0.621.7516.3547.99
Active/total xenografts at 10 μmol/L20/22 (90.9%)2/22 (9%)